Which target does crizotinib target?

Crizotinib is a tyrosine kinase receptor inhibitor targeting multiple targets and plays an important role in tumor treatment.

Crizotinib was originally developed as an inhibitor againstALK. ALK is a receptor tyrosine kinase. In certain types of tumors, such as non-small cell lung cancer (NSCLC), the ALK gene will be rearranged, resulting in abnormal protein expression, thereby promoting the growth and proliferation of tumor cells. Crizotinib can bind to ALK and inhibit its activity, thereby blocking the signal transduction of tumor cells and achieving the effect of treating tumors.

In addition to ALK, crizotinib has also been confirmed to have inhibitory effects on ROS1. ROS1 is also a receptor tyrosine kinase. In NSCLC and other tumors, ROS1 gene fusion can lead to abnormal cell proliferation. Crizotinib can also exert anti-tumor effects by inhibiting the activity of ROS1.

In addition to the above-mentioned main targets, crizotinib also has certain inhibitory effects on targets such as hepatocyte growth factor receptor (HGFR, also known as c-Met) and RON. These targets also play important roles in the growth, proliferation, and migration of tumor cells. By inhibiting the activity of these targets, crizotinib can further enhance its anti-tumor effect.

Crizotinib, as a tyrosine kinase receptor inhibitor targeting multiple targets, provides a new method for tumor treatment. Especially in the treatment of NSCLC, crizotinib has shown significant efficacy in patients with ALK positive and ROS1 positive patients. Screening out patient groups suitable for crizotinib through genetic testing can achieve more precise and personalized treatment.